For research use only. Not for therapeutic Use.
Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein[1][2].
Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils[1].
Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers[1].
Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau[2].
Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29[2].
| Catalog Number | I044588 |
| CAS Number | 185351-23-9 |
| Synonyms | (2S)-2-[(3-chloro-1,4-dioxonaphthalen-2-yl)amino]-3-(1H-indol-3-yl)propanoic acid |
| Molecular Formula | C21H15ClN2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H15ClN2O4/c22-17-18(20(26)14-7-2-1-6-13(14)19(17)25)24-16(21(27)28)9-11-10-23-15-8-4-3-5-12(11)15/h1-8,10,16,23-24H,9H2,(H,27,28)/t16-/m0/s1 |
| InChIKey | ZKNQSBBALRSDBQ-INIZCTEOSA-N |
| SMILES | C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)NC(CC3=CNC4=CC=CC=C43)C(=O)O |
| Reference | [1]. V Guru KrishnaKumar, et al. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids. Sci Rep. 2018 Jan 8;8(1):71. [2]. Moran Frenkel-Pinter, et al. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. Neurodegener Dis. 2017;17(2-3):73-82. |
